Table 2 Left ventricular function and remodeling measured by LVG, TTE, CMRI, and SPECT.

From: Effects of different doses of granulocyte colony-stimulating factor mobilization therapy on ischemic cardiomyopathy

 

Control

(normal saline, 2 mL/d, n = 6)

Low-dose

(G-CSF, 2.5 μg/kg/d, n = 6)

Middle-dose

(G-CSF, 5 μg/kg/d n = 6)

High-dose

(G-CSF, 10 μg/kg/d, n = 6)

Systolic functional parameters

LVEF measured by LVG

Before modeling, %

75.0 ± 1.3

74.7 ± 4.2

73.7 ± 1.2

76.0 ± 3.0

4 weeks after modeling, %

55.8 ± 3.2

54.5 ± 5.4

53.6 ± 2.4

54.7 ± 5.6

8 weeks after modeling, %

51.9 ± 2.1*

54.9 ± 1.5*#

59.5 ± 2.1##†‡

55.5 ± 5.3*#‡

LVEF measured by TTE

Before modeling, %

74.6 ± 2.0

74.2 ± 3.5

73.3 ± 2.1

76.0 ± 3.0

4 weeks after modeling, %

53.2 ± 1.6

52.9 ± 3.8

54.7 ± 3.0

53.4 ± 2.4

8 weeks after modeling, %

50.6 ± 3.0*

53.2 ± 2.3*#

60.4 ± 3.6##†‡

55.8 ± 4.7*#‡

LVEF measured by CMRI

Before modeling, %

73.2 ± 1.6

72.5 ± 2.3

72.7 ± 3.5

74.0 ± 2.6

4 weeks after modeling, %

52.6 ± 2.7

52.9 ± 3.8

54.7 ± 3.0

53.4 ± 2.4

8 weeks after modeling, %

50.0 ± 3.0*

53.1 ± 2.3*#

60.1 ± 3.4##†‡

53.8 ± 2.5*#‡

LVEF measured by SPECT

Before modeling, %

74.8 ± 2.4

74.1 ± 1.6

73.5 ± 2.7

75.6 ± 3.2

4 weeks after modeling, %

54.7 ± 2.2

53.8 ± 4.3

54.0 ± 2.5

54.5 ± 4.8

8 weeks after modeling, %

51.2 ± 2.7*

54.3 ± 1.2*#

59.3 ± 4.0##†‡

55.0 ± 3.4*#‡

Diastolic functional parameters

E/A measured by TTE

4 weeks after modeling

1.0 ± 0.2

1.1 ± 0.2

1.0 ± 0.3

1.0 ± 0.2

8 weeks after modeling

0.9 ± 0.2*

1.2 ± 0.2*#

1.3 ± 0.3*#

1.2 ± 0.4*#

Ea/Aa measured by TTE

4 weeks after modeling

0.9 ± 0.3

0.9 ± 0.4

0.8 ± 0.4

0.9 ± 0.4

8 weeks after modeling

0.7 ± 0.3*

0.9 ± 0.2

1.0 ± 0.2*#

0.9 ± 0.3#

E/Ea measured by TTE

4 weeks after modeling

12.2 ± 4.2

12.1 ± 4.5

12.5 ± 3.7

12.4 ± 3.6

8 weeks after modeling

12.4 ± 3.4*

11.8 ± 2.8*#

11.0 ± 3.1*#†

11.0 ± 4.5*#

Diameter and volume of left ventricle

LVEDd measured by TTE

Before modeling, mm

32.7 ± 3.0

33.0 ± 2.7

34.1 ± 3.7

32.8 ± 2.8

4 weeks after modeling, mm

35.9 ± 2.9

36.3 ± 2.3

36.9 ± 3.2

35.9 ± 1.8

8 weeks after modeling, mm

36.2 ± 1.5

36.0 ± 2.4

35.8 ± 2.0*

36.0 ± 2.2

LVESd measured by TTE

Before modeling, mm

21.5 ± 3.0

19.3 ± 1.8

19.6 ± 2.5

20.4 ± 1.7

4 weeks after modeling, mm

23.5 ± 1.9

24.2 ± 2.1

23.8 ± 1.8

22.7 ± 1.5

8 weeks after modeling, mm

25.6 ± 2.6*

23.6 ± 2.3#

21.0 ±± 1.4*#†‡

21.9 ± 1.2#

LVEDV measured by CMRI

Before modeling, mm

32.2 ± 2.0

30.6 ± 2.3

31.4 ± 2.2

31.8 ± 2.1

4 weeks after modeling, mm

37.0 ± 3.2

35.7 ± 3.0

36.5 ± 2.5

37.1 ± 2.0

8 weeks after modeling, mm

37.7 ± 2.4

35.9 ± 2.9#

35.6 ± 2.0*‡

37.3 ± 1.6

LVESV measured by CMRI

Before modeling, mm

8.3 ± 3.7

7.6 ± 2.6

7.9 ± 3.2

8.1 ± 1.6

4 weeks after modeling, mm

13.8 ± 2.6

13.0 ± 1.8

13.2 ± 2.4

14.0 ± 2.7

8 weeks after modeling, mm

15.0 ± 2.0*

12.2 ± 2.3#

11.6 ± 3.1*#†‡

13.5 ± 1.8#

Left ventricular motion

8 weeks after modeling

Improved, N

8

7

2#†‡

3#†

Unimproved, N

2

3

7#†‡

3

Ischemic area

Size of left ventricular infarct measured by CMRI

4 weeks after modeling, %

5.2 ± 2.1

4.9 ± 1.6

4.8 ± 2.8

5.1 ± 2.6

8 weeks after modeling, %

6.5 ± 1.5*

4.8 ± 2.0#

4.0 ± 1.7*#†‡

4.7 ± 2.0#

Myocardial perfusion defects measured by SPECT

4 weeks after modeling, %

11.2 ± 3.0

10.4 ± 1.4

10.9 ± 2.8

12.0 ± 3.4

8 weeks after modeling, %

15.2 ± 2.5*

8.7 ± 2.6*#

6.2 ± 2.3*#†‡

8.9 ± 2.0*#

  1. LVG, left ventriculography; TTE, transthoracic echocardiography; CMRI, cardiac magnetic resonance imaging; SPECT, single photon emission computed tomography; LVEF, left ventricular ejection fractions; E, mitral E peak; A, mitral E peak; LVEDd, left ventricular end diastolic diameter; LVESd, left ventricular end systolic diameter; LVEDV, left ventricular end diastolic volume; LVESV; left ventricular end systolic volume.
  2. *P < 0.05 compared with 4 weeks after modeling; #P < 0.05 compared with control group; †P < 0.05 compared with low dose group; ‡P < 0.05 compared with high dose group.
Back to article page